Race Oncology is please update our shareholders on the clinical progress of bisantrene. This talk was presented by Race Oncology’s CSO Dr Daniel Tillett at the IRD Invest virtual conference on the 29th July 2019.
L36, 1 Macquarie Place, Sydney
+61 2 8051 3043
Race Oncology is a specialty pharmaceutical company whose business model is to pursue later stage drug assets, principally in the cancer field. Our first important asset is a chemotherapy drug called Bisantrene.
Get the latest news and updates